$0.88
-0.02(-1.84%)
Mkt Cap $64M
$0.24
$3.18
52-Week Range
At a Glance
AI-generatedCognition Therapeutics, Inc.
8-K
Cognition Therapeutics, Inc. reported financial results for the year ended December 31, 2025, with a net loss of $23.5 million or $(0.32) per share, improved from $34.0 million or $(0.86) per share in 2024, and cash of $37.0 million sufficient through Q2 2027. The company provided clinical updates on zervimesine, including published Phase 2 SHIMMER results in DLB psychosis, planned FDA meeting mid-2026, and completed enrollment in Phase 2 START trial in early Alzheimer's with results in 2027.$64M
Market Cap
—
Revenue
-$26M
Net Income
Employees25
Fundamentals
How The Business Makes Money
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001455365
ISINUS19243B1026
CUSIP19243B102
Phone412 481 2210
Address2500 Westchester Avenue, Purchase, NY, 10577, US
SEC EDGAR